NBDC Research ID: hum0354.v2
SUMMARY
Aims: In recent years, the detection and measurement of peripheral circulating tumor cells (CTC) has attracted attention as a useful method for diagnosing solid tumors, metastasis, recurrence, and prognosis. Unlike conventional tumor markers, cancer cells themselves are collected from the patient's peripheral blood, which is a means that enables a highly reliable diagnosis. In addition, the method has the advantage of being non-invasive and capable of time-series analyses. The purpose of this study is to collect CTCs from patients with advanced urogenital cancer, especially metastatic castration-resistant prostate cancer (CRPC), and analyze molecular expression abnormalities, and establish them as tumor markers for therapeutic effect determination and prognosis prediction.
Methods: CTCs are collected from CRPC patients receiving enzalutamide, docetaxel, or cabazitaxel.
Participants/Materials: Patients with advanced metastatic CRPC undergoing drug treatment at Juntendo University Hospital
| Dataset ID | Type of Data | Criteria | Release Date |
|---|---|---|---|
| hum0354.v1.qRT-PCR.v1 | qRT-PCR | Unrestricted-access | 2022/06/30 |
| hum0354.v2.qRT-PCR.v1 | qRT-PCR | Unrestricted-access | 2023/04/18 |
*When the research results including the data which were downloaded from NHA/DRA, are published or presented somewhere, the data user must refer the papers which are related to the data, or include them in the acknowledgment. Learn more
MOLECULAR DATA
hum0354.v1.qRT-PCR.v1 / hum0354.v2.qRT-PCR.v1
| Participants/Materials |
CRPC (ICD10: C61): 127 cases 1. patients receiving cabazitaxel: 48 cases (150 CTC samples) 2. patients receiving enzalutamide: 90 cases (46 CTC samples) |
| Targets | qRT-PCR |
| Target Loci for Capture Methods | androgen receptor expression, splicing variant 7 (AR-V7) |
| Platform |
qPCR kit: Adns Test Prostate Cancer Panel AR-V7（Qiagen） qPCR instrument: BioRad T100 Thermal cycler |
| Source | mRNAs extracted from CTC |
| Cell Lines | - |
| Software for analyzing the quantitative expression | Experion Software Version 3.0 |
| NBDC Dataset ID |
(Click the Dataset ID to download the file) |
| Total Data Volume |
1. 23 KB (xlsx) 2. 20 KB (xlsx) |
| Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Masayoshi Nagata
Affiliation: Urology, Graduate School of Medicine, Juntendo University
Project / Group Name:-
Funds / Grants (Research Project Number):
| Name | Title | Project Number |
|---|---|---|
PUBLICATIONS
| Title | DOI | Dataset ID | |
|---|---|---|---|
| 1 | Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer | doi: 10.1371/journal.pone.0226219 | hum0354.v1.qRT-PCR.v1 |
| 2 | Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer | doi: 10.1038/s41598-022-22854-1 | hum0354.v1.qRT-PCR.v1 |
| 3 | Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases | doi: 10.1038/s41598-023-35790-5 | hum0354.v2.qRT-PCR.v1 |
